We’re thrilled to see #TBCPartner @VerveTx on the #Endpoints11 list of the most promising and disruptive biotech companies of 2020. Verve aims to tackle cardiovascular disease around the globe with gene-editing technologies. https://bit.ly/3n2yem9 #eleven20

@tenbridge